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Background: Heart failure (HF) is a major health problem in older adults but the use and dosing of evidence-based medications for systolic 
dysfunction in an outpatient population has not been well studied.
Methods: The use of ACE-Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB), and Beta Blockers (BB) in outpatients with HF was investigated 
using results from the STAMINA-HFP Registry, a prospective, observational study that enrolled patients from specialty clinics in the UNITE-HF network 
and community cardiology sites with HF experience. Patients with systolic HF (EF <40%) were divided into groups: <55, 55-75, and >75 years old. 
The frequency of the current use of ACEI, BB, and ARB, and current doses of ACEI and BB ≥ mean clinical trial doses (MCTD) at enrollment were 
compared. Total daily doses of ACEI and BB were converted to mg equivalents of enalapril or metoprolol succinate. MCTD of ACEI and BB were 
established based on mean doses achieved in mortality trials (enalapril 16.6 mg qd and metoprolol succinate 159 mg qd).
Results: This cohort (n=816) was 37% female, 71% Caucasian, with a mean (± SD) age of 63 ± 14 years and baseline hemoglobin of 13.3 ± 2.0 g/dL. 
Medications < 55 (n=149) 55 - 75 (n=502)
> 75
(n=165)
Overall
P value
55-75 vs. >75 P value
BB % 94 84 77 0.001 0.039
% ≥ MCTD of BB 53 40 30 0.001 0.038
ACEI % 85 77 62 0.001 0.001
% ≥ MCTD of ACEI 59 60 33 0.001 0.001
ARB % 12 19 25 0.012 0.115
ACEI or ARB % 93 92 85 0.007 0.004
ACEI and BB (%) 81 67 51 0.001 0.001
ACEI or ARB and BB (%) 88 79 67 0.001 0.002
% ≥ MCTD of ACEI and BB 35 30 11 0.001 0.001
Conclusion: Older patients (>75 years) with HF were significantly less likely to receive ACEI and BB, alone or in combination, and to achieve doses 
of these drugs used in mortality trials. Whether age-related differences in drug use and dosing are explained by differences in baseline clinical 
characteristics or physician bias is under investigation.
